Oncology

Latest News

Top 5 Most-Read Oncology Content of 2024

December 25th 2024

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Most Popular Articles of 2024 in Evidence-Based Oncology

By Mary Caffrey

December 23rd 2024

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 12th 2016

FDA Update in Oncology, February 2016

Surabhi Dangi-Garimella, PhD

Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

February 12th 2016

Managed Care Updates in Oncology, February 2016

Surabhi Dangi-Garimella, PhD

A summary of updated breast cancer screening guidelines, MEDPAC recommendations for 340B, and disparity in survival of young patients with Hodgkin lymphoma.

February 11th 2016

Does Genetic Testing Impact Treatment Decisions in Breast Cancer?

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology found that the knowledge of genetic risk influenced surgical treatment decisions in women younger than 40 years who were diagnosed with breast cancer.

February 11th 2016

Cancer MoonShot 2020 Proposes a Collaborative Precision Cancer Care Model

Surabhi Dangi-Garimella, PhD

At the annual JP Morgan Healthcare Conference, Patrick Soon-Shiong, MD, introduced Cancer MoonShot, his vision for a coalition to improve cancer outcomes. His claims on federal support for the project, however, stirred some controversy.

February 11th 2016

Shaping the Future of Immuno-Oncology

Joseph Alvarnas, MD

While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.

February 11th 2016

Study Compares Filgrastim vs Tbo-Filgrastim in Patients With Myeloma

Priyam Vora

While there are no significant differences in the results between filgrastim and tbo-filgrastim in a clinical setting, tbo-filgrastim offers significant cost savings over filgrastim.

February 10th 2016

New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE

Surabhi Dangi-Garimella, PhD

Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.

February 10th 2016

Patient Assistance: Implementing Preventative Steps to Ensure Financial Wellness

Jacqueline Cab&aacute n Charles Lynch

An overview of patient assistance programs at Smilow Cancer Hospital at Yale-New Haven, including their innovative hospital-based explanation of benefits form, which can eliminate patient responsibilities and help expedite the turnaround times for payment processing with copay assistance.

February 10th 2016

Patient Access to Immuno-Oncology Agents - A US Policy Perspective

Surabhi Dangi-Garimella, PhD

The cost issues with immuno-oncology agents are real, but so is the value that they bring to the table. How can we improve access to these agents at a reasonable cost?

February 10th 2016

Study Hopes to Resolve Questions About Management of Pre-Cancers of the Breast

Jackie Syrop

As physicians and researchers question whether certain treatments for early signs of breast cancer are necessary, the first large US study will seek to determine the best way to manage ductal carcinoma in situ.

February 9th 2016

Strong Gains for Healthcare and Research in President Obama's 2017 Budget

Surabhi Dangi-Garimella, PhD

Innovation has remained high on the administration’s agenda, as is evident from the allocations to tackle climate changes as well as find treatments for devastating health conditions.

February 9th 2016

Access to Immuno-Oncology Therapies - European Policy Perspective

Suzanne Wait, PhD

Ensuring rapid, appropriate, and sustainable access to immuno-oncology therapies for patients in Europe: what role can policies play?

February 8th 2016

ASCO Recommends Biomarker Use to Guide Early Breast Cancer Therapy Decisions

Surabhi Dangi-Garimella, PhD

The panel members that have proposed the recommendations have found clinical utility for several genomic tests to guide clinical decision in women with early stage breast cancer.

February 8th 2016

PhRMA Plans Targeted Ad Campaign in Wake of Focus on Drug Costs

Mary Caffrey

The ads will be targeted at about 7000 "influencers" including lawmakers who could control whether drug prices are regulated. Many have called for Medicare to gain the right to negotiate drug prices.

February 8th 2016

Evolving Practices in Managing Costly Immunotherapy

Carina Verdier Dolan, PharmD, BCOP

To address the nationwide concern of costly immunotherapy agents, this article features health system inpatient and outpatient strategies that can help mitigate their costs.

February 8th 2016

PCPs Diligent With Following USPSTF Recommendations on PSA Testing

Surabhi Dangi-Garimella, PhD

Using data gathered from the National Ambulatory Medical Care Survey, the authors of a JAMA Internal Medicine study identified a significant decrease in PSA testing referrals by primary care physicians compared with urologists.

February 7th 2016

What We Know About California's Right-to-Die Law, Except When It Takes Effect

Mary Caffrey

A quirk in California law means the law that Governor Jerry Brown signed with much fanfare last fall hasn't taken effect yet, even though its passage is having ripple effects.

February 7th 2016

Considering the Burden on Family Caregivers

Priyam Vora

A deeper understanding of the interdependencies among the patients, family caregivers, and service providers revealed that if general practice teams intervene early, they may be more likely meet patients’ needs in the end-of-life care process.

February 6th 2016

Lipegfilgrastim a Possible Alternative for Managing Chemotherapy-Induced Neutropenia

Jessica Men

The novel molecule lipegfilgrastim has been shown to be relatively equivalent to pegfilgrastim in the management of chemotherapy-induced neutropenia among patients with breast cancer.

February 5th 2016

AJMC Staff

Scientists at the FDA have provided their recommendation to be submitted to an independent medical advisory panel that will decide the fate of Remsima.

February 5th 2016

Cancer Treatment Financially Devastating in Young Adult Survivors, Says Samfund Study

Surabhi Dangi-Garimella, PhD

The paper in Cancer Medicine finds that cancer has a devastating and age-specific impact on the finances of young adult survivors.

February 5th 2016

Where Does Immuno-Oncology Fit in a Value-Based Care Delivery Model?

Bruce Feinberg, DO

Advances made in the field of immuno-oncology (I-O) in 2015 have greatly expanded our understanding of I-O and added more complexity to its value assessment.

February 5th 2016

The Fight of Our Lives: Confronting the Unmet Need in Lung Cancer

Bonnie J. Addario

Supporting, funding, and protecting the research and development of new medicines and new treatments is more critical, now than ever, to provide better treatments and better outcomes to all cancer patients.

February 4th 2016

High Risks, High Costs Associated With Febrile Neutropenia in Metastatic Cancer

Jackie Syrop

Data from 2 large studies of patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients. Associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients.

February 4th 2016

ASCO Highlights the Year in Oncology Advances

Laura Joszt, MA

The annual Clinical Cancer Advances report from the American Society of Clinical Oncology highlights the accomplishments made in the last year in the fight against cancer.

February 4th 2016

On World Cancer Day, Stories of Courage and Support

Surabhi Dangi-Garimella, PhD

On World Cancer Day, The American Journal of Managed Care would like to acknowledge the determination of cancer survivors and the support provided by various organizations to patients and their families.

February 4th 2016

Immuno-Oncology 2016 and Beyond: The Opportunities, Challenges, and Risks

Michael V. Seiden, MD, PhD

The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.

February 3rd 2016

Fight With or Adapt to Rising Drug Prices? Economists Debate at the AcademyHealth Conference

Surabhi Dangi-Garimella, PhD

Rising drug prices, the effect on the healthcare system, consumer push-back, and possible solutions were debated by the expert panel.

February 3rd 2016

Molecular Testing Patterns in Metastatic Non—Small Cell Lung Cancer

Elizabeth MacLean, PharmD Anthony Louder, PhD, RPh Kim Saverno, PhD, RPh Gregory Smith, BA Jack Mardekian, PhD Cari Bruins, PharmD Melea Ward, PharmD, PhD Robert Sweetman, MD Margaret Pasquale, PhD

Assessment of the timing of histologic and molecular testing indicates that testing occurred prior to treatment initiation for most patients with metastatic nonâ€”small cell lung cancer.

February 2nd 2016

Rationing Care in Times of Drug Shortages

Surabhi Dangi-Garimella, PhD

Pediatric oncologists from across the country covened a task force to develop an ethical framework that guides decisions on allocation based on curability, prognosis, and the incremental importance of a drug to a patient’s outcome

...

105 106 107 108 109 110 111 112 113

...

181 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions